Future vaccine development at NICHD

Annals of the New York Academy of Sciences

Volumn 1038, Issue , 2004, Pages 49-59

  Robbins, John B ^a,b   Schneerson, Rachel ^b  

^a Lab of Devmtl and Molec Immunity   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Capsular polypeptide; Capsular polysaccharide; O specific polysaccharide; Pertussis toxin; Serum IgG

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; IMMUNOGLOBULIN G; PERTUSSIS TOXIN;

ANTHRAX; ANTIBODY BLOOD LEVEL; BACILLUS ANTHRACIS; BORDETELLA PERTUSSIS; CONFERENCE PAPER; DRUG EFFICACY; ESCHERICHIA COLI O157; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; SALMONELLA; SALMONELLA TYPHI; SHIGELLA; SHIGELLOSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER;

BACILLUS ANTHRAX; BORDETELLA PERTUSSIS; ESCHERICHIA COLI; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE B; MENINGOCOCCUS; PNEUMOCOCCUS; SALMONELLA; SALMONELLA TYPHI; SHIGELLA; STAPHYLOCOCCUS AUREUS;

EID: 17744375202     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1315.011     Document Type: Conference Paper

References (61)

1. ROBBINS, J.B., R. SCHNEERSON & S.C. Szu. 1995. Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171: 1387-1398.
2. ROBBINS, J.B., R. SCHNEERSON, P. ANDERSON & D.H. SMITH. 1996. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: impact on public health and implications for other polysaccharide-based vaccines. JAMA 276: 1181-1185.
3. ROBBINS, J.B., R. SCHNEERSON, S.C. Szu, et al. 1998. Standardization may suffice for licensure of conjugate vaccines. Dev. Biol. Stand. 95: 161-167.
4. RODRIGUES, L.P., R. SCHNEERSON & J.B. ROBBINS. 1971. Immunity to Haemophilus influenzae type b. I. The isolation, and some physicochemical, serologic, and biologic properties of the capsular polysaccharide of Haemophilus influenzae type b. J. Immunol. 107: 1071-1080.
5. SCHNEERSON, R., L.P. RODRIGUES, J.C. PARKE, JR. & J.B. ROBBINS. 1971. Immunity to disease caused by Haemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Immunol. 107: 1081-1089.
6. SCHNEERSON, R. & J.B. ROBBINS. 1971. Age-related susceptibility to Haemophilus influenzae type b disease in rabbits. Infect. Immun. 4: 397-401.
7. SCHNEERSON, R., M. BRADSHAW, J.K. WHISNANT, et al. 1971. An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera towards H. influenzae type b. J. Immunol. 108: 1551-1562.
8. PARKE, J.C., JR., R. SCHNEERSON & J.B. ROBBINS. 1972. The attack rate, incidence, racial distribution and case fatality rate of Haemophilus influenzae type b meningitis in Mecklenburg County, North Carolina. J. Pediatr. 81: 765-769.
9. ROBBINS, J.B., R.L. MYEROWITZ, J.K. WHISNANT, et al. 1972. Enteric bacteria cross-reactive with N. meningitidis groups A and C and Diplococcus pneumoniae types I and III. Infect. Immun. 6: 651-656.
10. ROBBINS, J.B., J.K. WHISNANT, R. SCHNEERSON & J.C. PARKE, JR. 1973. Quantitative measurement of the "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7(3): 103-110.
11. SCHNEERSON, R. & J.B. ROBBINS. 1975. Induction of serum Haemophilus influenzae type b capsular antibodies in adult volunteers fed cross-reacting Eschenchia coli 075:K100:H5. N. Engl. J. Med. 292: 1093-1096.
12. PARKE, J.C., JR, R. SCHNEERSON, J.B. ROBBINS & J.J. SCHLESSELMAN. 1977. Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg County, North Carolina (March 1974-March 1976). J. Infect. Dis. 136: S51-S56.
13. SCHNEERSON, R., O. BARRERA, A. SUTTON & J.B. ROBBINS. 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152: 361-376.
14. SUTTON, A., R. SCHNEERSON, S. KENDALL-MORRIS & J.B. ROBBINS. 1982. Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect. Immun. 35: 95-104.
15. TARR, P.I., S.W. HOSEA, E.J. BROWN, et al. 1982. The requirement of specific anti-capsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J. Immunol. 128: 1772-1775.
16. CHU, C., R. SCHNEERSON, J.B. ROBBINS & S.C. RASTOGI. 1983. Further studies on immunogenicity of Haemophilus influenzae type b and pneumococcal 6A polysaccharide-protein conjugates. Infect. Immun. 40: 245-256.
17. EGAN, W., R. SCHNEERSON, K.E. WERNER & G. ZON. 1982. Structural studies and chemistry of bacterial capsular polysacchawrides isolated from Haemophilus influenzae types a,b,c amd f: NMR spectroscopic identification and chemical modification of endgroups and the nature of based-catalyzed hydrolytic depolymeriation. J. Am. Chem. Soc. 104: 2898-2910.
18. SCHNEERSON, R., J.B. ROBBINS, J.C. PARKE, Jr., et al. 1986. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect. Immun. 52: 519-528.
19. CLAESSON, B.A., R. SCHNEERSON, B. TROLLFORS, et al. 1999. Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month old children. J. Pediatr. 116: 929-931.
20. PARKE, J.C., JR., R. SCHNEERSON, C. REIMER, et al. Clinical and immunologic responses to Haemophilus influenzae type b tetanus toxoid conjugate vaccine in infants injected 3,5,7 and 18 months of age. J. Pediatr. 118: 84-190.
21. CLAESSON, B.A., B. TROLLFORS, P.W. ANDERSON, et al. 1996. Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 15(2):170-172.
22. Szu, S.C., C-J. LEE, J.C. PARKE, JR, et al. 1982. Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers. Infect. Immun. 35: 777-782.
23. ROBBINS, J.B., R. AUSTRIAN, C-J. LEE, et al. 1983. Consideration for formulating the second generation pneumococcal vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148: 1136-1159.
24. Szu, S.C., G. ZON, R. SCHNEERSON & J.B. ROBBINS. 1986. Characterization of the depolymerization of bacterial polysaccharides induced by ultrasonic irradiation. Carbohydr. Res. 152: 7-20.
25. Szu, S.C., R. SCHNEERSON & J.B. ROBBINS. 1986. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal infection with encapsulated pneumococci. Infect. Immun. 54: 448-455.
26. FATTOM, A., W.F. VANN, S.C. Szu, et al. 1988. Synthesis and physiochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect. Immun. 56: 2292-2298.
27. SCHNEERSON, R., L. LEVI, J.B. ROBBINS, et al. 1992. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect. Immun. 60: 3528-3532.
28. VANN, W.F., T.-Y. LIU & J.B. ROBBINS. 1976. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect. Immun. 13654-13662.
29. WONG, K.H., O. BARRERA, A. SUTTON, et al. 1977. Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J. Biol. Stand. 5(3): 197-215.
30. DEVI, S.J.N., J.B. ROBBINS & R. SCHNEERSON. 1991. Antibodies to poly[(2→8)-alpha-N-acetylneuraminic acid] and poly[(2→9)-alpha-N- acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl. Acad. Sci. USA 88: 7175-7179.
31. ROBBINS, J.B., D.W. TOWNE, E.G. GOTSCHLICH & R. SCHNEERSON. 1997. "Love's labours lost;" failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 350: 880-882.
32. ROBBINS, J.B., R. SCHNEERSON & E.G. GOTSCHLICH. 2000. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. 19: 945-953.
33. ROBBINS, J.B., R. SCHNEERSON, E.G. GOTSCHLICH, et al. 2003. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull. WHO 81: 745-750.
34. ROBBINS, J.D. & J.B. ROBBINS. 1984. Re-examination of the immunopathogenic role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 150: 436-449.
35. ACHARYA, I.L., C.U. LOWE, R. THAPA, et al. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report one year after immunization. N. Engl. J. Med. 317: 1101-1104.
36. KLUGMAN, K.P., I.T. GILBERTSON, H.J. KOORNHOF, et al., Vaccine Advisory Committee. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii: 1165-1169.
37. Szu, S.C., A.L. STONE, J.D. ROBBINS, et al. 1987. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166: 1510-1524.
38. KOSSACZKA, Z., F-YC. LIN, V.A. Ho, et al. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers and 2- to 4-year-old children in Vietnam. Infect. Immun. 67: 5806-5810.
39. LIN, F-YC., V.A. Ho, P.V. BAY, et al. 2002. The epidemiology of typhoid fever in the Dong Thap Province, MeKong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 62: 644-648.
40. LIN, F-YC., V.A. Ho, H.B. KHIEM, et al. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
41. LANH, M.N., F-YC. LIN, P.V. BAY, et al. 2003. Persistence of antibodies and efficacy against typhoid fever 28-46 months following Vi conjugate vaccine (Vi-rEPA) in 2 to 5 years-old children. N. Engl. J. Med. 349: 1390-1391.
42. KONADU, E., J. SHILOACH, D. A. BRYLA, et al. 1996. Synthesis, characterization and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid, with emphasis on the role of O-acetyls. Infect. Immun. 64: 2709-2715.
43. KONADU, E.Y., F-YC. LIN, V.A. Ho, et al. 2000. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers and 2-to-4-year-old children in Vietnam. Infect. Immun. 68: 1529-1534.
44. ROBBINS, J.B., C. CHU, D.C. WATSON, et al. 1991. O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of Shigellosis and related diseases. Rev. Infect. Dis. 13: S362-S365.
45. CHU, C., B. LIU, D. WATSON, et al. 1991. Preparation, characterization and immunogenicity of conjugates composed of O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect. Immun. 59: 4450-4458.
46. ROBBINS, J.B., C. CHU & R. SCHNEERSON. 1992. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15: 346-361.
47. COHEN, D., S. ASHKENAZI, M.S. GREEN, et al. 1997. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnet conjugate vaccine in young adults. Lancet 349: 155-159.
48. ASHKENAZI, S., J.H. PASSWELL, E. HARLEV, et al., and The Israel Pediatric Shigella Study Group. 1999. Safety and immunogenicity of Shigella sonnet and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J. Infect. Dis. 179: 1565-1568.
49. POZSGAY, V., C. CHU, L. PANNELL, et al. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96: 5194-5197.
50. PAVLIAKOVA, D., J.S. MONCRIEF, D.M. LYERLY, et al. 2000. Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect. Immun. 68: 2161-2166.
51. succ conjugates in 1 to 4-year-old children. Pediatr. Infect. Dis. J. 22: 701-706.
52. KONADU, E.Y., J.B. ROBBINS, J. SHILOACH, et al. 1994. Preparation, characterization and immunological properties in mice of Escherichla coli 0157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 62: 5048-5054.
53. KONADU, E.Y., J.C. PARKE, JR., H.T. TRAN, et al. 1998. Investigational vaccine for Escherichia coli 0157: Phase 1 study of 0157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugates in adults. J. Infect. Dis. 177: 383-387.
54. RAMIREZ, D.M., S. LEPPLA, R. SCHNEERSON & J. SHILOACH. 2002. Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J. Ind. Microbiol. Biotech. 28: 232-238.
55. SCHNEERSON, R., J. KUBLER-KIELB, T-Y. LIU, et al. 2003. Poly(γ-D-glutamic acid protein) conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis. Proc. Natl. Acad. Sci. USA 100: 8945-8950.
56. KARAKAWA, W.W., J.M. FOURNIER, W.F. VANN, et al. 1985. Methods for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J. Clin. Microbiol. 22: 445-447.
57. SOMPOLINKSKY, O., Z. SAMRA, W.W. KARAKWAWA, et al. 1988. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources in relation to phage types. J. Clin. Microbiol. 22: 828-834.
58. KARAKAWA, W.W., A. SUTTON, R. SCHNEERSON, et al. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun. 56: 1090-1095.
59. FATTOM, A., R. SCHNEERSON, D.C. WATSON, et al. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 610: 1023-1032.
60. WELCH, P.G., A. FATTOM, J. MOORE, JR., et al. 1996. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysacchande- Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Am. Soc. Nephrol. 7: 247-253.
61. SHINEFIELD, H., S. BLACK, A.I. FATTOM, et al. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346: 491-496.